Side-by-side · Research reference
SurvodutidevsTestagen
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
APhase 3HUMAN-REVIEWED25/54 cited
BAnimal-MechanisticHUMAN-REVIEWED11/41 cited
Survodutide
GLP-1/Glucagon Dual Agonist · Phase 3
SQ · Once Weekly
Testagen
Bioregulator Peptide · Khavinson School
SQ · Abdomen · Cyclical
01Mechanism of Action
Parameter
Survodutide
Testagen
Primary target
GLP-1 receptor and glucagon receptor (GCGR)Yathindra 2026Zimmermann 2026
Testicular tissue; proposed nuclear DNA interaction
Pathway
Central: CVOs → hypothalamic appetite regulation. Peripheral: GLP-1R → incretin effect; GCGR → hepatic lipid metabolism, energy expenditureZimmermann 2026Long 2026
Nuclear penetration → DNA/oligonucleotide binding → gene expression modulation (bioregulator hypothesis)Fedoreyeva 2011
Downstream effect
Decreased energy intake, increased energy expenditure, improved glucose homeostasis, hepatic fat reductionZimmermann 2026Yathindra 2026
Proposed support for spermatogenesis and testicular function; mechanistic data limited to nuclear localization and DNA interactionFedoreyeva 2011
Feedback intact?
—
Unknown — no HPG axis data
Origin
—
Khavinson bioregulator school — isolated from testicular tissue peptide fractions
Antibody development
—
—
02Dosage Protocols
Parameter
Survodutide
Testagen
Frequency
Once weekly
Once daily or alternate days
Evidence basis
Phase 2 RCT (obesity) · Phase 3 ongoing
Animal mechanistic / in vitro onlyFedoreyeva 2011
Typical protocol (anecdotal)
—
100–200 mcg / day
No published human dosing studies; derived from Russian bioregulator practice.
Cycle length
—
10–20 days on, 10–14 days off
Bioregulator tradition uses pulsed cycles; no controlled data.
Reconstitution
—
Sterile water or bacteriostatic saline
Half-life
—
Unknown — likely minutes (short peptide)
03Metabolic / Fat Loss Evidence
Parameter
Survodutide
Testagen
Primary fat target
Total body weight, visceral adipose tissue
—
Weight loss mechanism
Dual action: decreased energy intake + increased energy expenditureZimmermann 2026
—
Phase 2 efficacy
Significant weight loss demonstrated
Specific percentage not disclosed in abstracts.
—
Metabolic markers
Improvements in ALT, AST, LDL levels; significant ALT reduction (MD -22.10 vs placebo)Yathindra 2026Abulehia 2026Andonie 2026
—
Network meta-analysis
Favorable efficacy profile vs other glucagon receptor agonists
—
Comparative efficacy
Network meta-analysis shows competitive efficacy in GRA class
—
04Side Effects & Safety
Parameter
Survodutide
Testagen
GI symptoms
Diarrhea, nausea, fatigue — class effect of GLP-1 agonists
—
Safety profile
Network meta-analysis: comparable safety to other GRAs
—
Serious adverse events
Monitored in Phase 2/3; no unique safety signals reported
Detailed SAE data pending Phase 3 completion.
—
Injection site reactions
Expected with subcutaneous administration
Erythema, mild irritation (potential)
Glucagon-related effects
Potential for tachycardia, increased blood pressure — theoretical glucagon effect
—
Systemic effects
—
Unknown — no human safety data
Hormonal impact
—
No published data on testosterone, LH, FSH effects
Long-term safety
—
Unknown — no long-term studies
Absolute Contraindications
Survodutide
- ·Personal or family history of medullary thyroid carcinoma (class effect)
- ·Multiple endocrine neoplasia syndrome type 2
Testagen
- ·Active testicular malignancy
Relative Contraindications
Survodutide
- ·Severe GI disease (inflammatory bowel disease, gastroparesis)
- ·History of pancreatitis
- ·Cardiovascular disease (monitor closely for glucagon effects)
Testagen
- ·Hormone-sensitive cancers (no data; theoretical caution)
- ·Pregnant or breastfeeding (no data)
05Administration Protocol
Parameter
Survodutide
Testagen
1. Reconstitution
Specific reconstitution protocol not yet publicly disclosed. Follow manufacturer instructions upon approval.
Add 1–2 mL sterile or bacteriostatic water to lyophilised vial. Swirl gently; do not shake. Solution should be clear.
2. Injection site
Subcutaneous — abdomen, thigh, or upper arm. Rotate sites weekly to minimize injection site reactions.
Subcutaneous — abdomen or thigh. Rotate sites daily. Use standard insulin syringe (27–31G).
3. Timing
Once weekly, same day each week. Can be administered at any time of day, with or without meals.
Morning or evening; no established optimal timing. Anecdotal preference: evening to align with circadian testosterone patterns.
4. Storage
Store refrigerated (2–8 °C) until use. Do not freeze. Protect from light. Specific reconstituted storage duration pending labeling.
Lyophilised: room temp, dark. Reconstituted: refrigerate 2–8 °C, use within 14–21 days if bacteriostatic water used.
5. Needle
Subcutaneous injection with appropriate gauge needle (typically 27–31G). Use sterile technique.
10–20 days on, 10–14 days off. Bioregulator tradition uses pulsed exposure; rationale: prevent receptor/pathway desensitisation.